Summary: Bioavailability is the percentage of administered peptide reaching systemic circulation in active form. Oral peptides face digestive destruction and absorption barriers, producing lower bioavailability than injected peptides. Distribution determines where peptide concentrates—determined by receptor distribution, size, and protein binding. Metabolism occurs through enzymatic degradation and oxidation, varying based on peptide sequence and individual genetics. Kidney and liver eliminate metabolites, with variation based on organ function and age. Repeated dosing produces accumulation reaching steady state where dose equals elimination. Individual variations in bioavailability explain different responses to standard peptide doses.
What Bioavailability Means
Bioavailability is the percentage of administered peptide that reaches systemic circulation (the bloodstream) in active form. If you inject 100 micrograms of peptide directly into muscle, nearly 100% enters the bloodstream—bioavailability is roughly 100%. If you take 100 micrograms orally, much less reaches the bloodstream because digestive enzymes break it down—bioavailability might be 5-20%.
Bioavailability matters because only peptide reaching the bloodstream can travel to distant target tissues and produce effects. Peptide destroyed in the gut contributes no therapeutic benefit.
Different routes of administration produce different bioavailability. Intravenous (IV) injection produces maximum bioavailability (100%) because peptide goes directly into bloodstream. Intramuscular (IM) injection produces high bioavailability (typically 80-100%) depending on absorption from muscle tissue. Subcutaneous (SC) injection produces lower bioavailability than IM but still substantial (typically 50-90%). Oral produces lowest bioavailability (typically 5-30%) due to digestive degradation.
Absorption: Peptides Entering Circulation
Absorption is the process of peptide crossing barriers and entering bloodstream. Different routes have different absorption characteristics.
Oral Absorption Challenges
Oral peptides face enormous challenges. The stomach contains gastric acid and proteases that degrade peptides. The small intestine contains intestinal proteases that break peptides into smaller pieces. These digestive enzymes evolved to break down dietary proteins into individual amino acids for absorption.
Peptides surviving the digestive tract must cross the intestinal epithelium. The epithelial barrier is designed to absorb individual amino acids from protein digestion, not larger peptides. Most peptides are too large and hydrophobic (water-fearing) to cross efficiently. Some peptides have mechanisms allowing transport—specific peptide transporters recognize certain sequences and actively transport them across the epithelium.
Stomach pH affects absorption. Peptides are more stable at neutral pH than at acidic pH. Coating peptides with protective substances can help them survive stomach acid and reach the small intestine more intact. Some formulations use enteric coatings that dissolve only in the small intestine’s neutral pH.
Size dramatically affects absorption. Dipeptides and tripeptides (two and three amino acids) often absorb better than longer peptides because they’re smaller and less degraded. This is why some research focuses on short peptide fragments—they’re more likely to survive digestion and absorb.
Injection Absorption
Injected peptides don’t face digestive destruction, so absorption depends on local tissue factors. Intramuscular injection deposits peptide into muscle tissue. Blood flow to muscle carries the peptide away into systemic circulation. The rate depends on blood flow and how readily peptide dissolves in local tissue fluids.
Subcutaneous injection deposits peptide in the fat layer under skin. Absorption is slower than intramuscular because subcutaneous tissue has lower blood flow. Duration is often longer though—peptide releases gradually from subcutaneous depot into circulation, maintaining steady levels.
Intravenous injection eliminates the absorption step—peptide is already in circulation. This produces immediate peak levels but also faster elimination once metabolism begins.
Distribution: Peptides Traveling Through Body
After absorption, peptide travels through bloodstream to tissues. Distribution describes how widely peptide spreads and where it concentrates.
Many peptides are hydrophilic (water-loving) and don’t cross the blood-brain barrier efficiently. The blood-brain barrier is a selective barrier preventing most water-loving molecules from crossing. Peptides often can’t reach brain tissue unless they’re specifically transported.
Some peptides are hydrophobic (water-fearing) and don’t dissolve well in blood. These peptides attach to blood proteins, which serve as carriers. Albumin is a major protein carrier. Peptides bound to carriers can’t access tissue receptors. Binding to carriers affects distribution and prolongs circulation time because carriers prevent kidney elimination.
Peptide distribution also depends on receptor distribution. A peptide with receptors primarily in muscle tissue concentrates in muscle, not in other tissues. Tissues with high receptor density accumulate more peptide. This selective distribution focuses effects to target tissues.
Volume of distribution (Vd) describes how extensively a peptide distributes. A small Vd means peptide remains mostly in blood. A large Vd means peptide spreads widely into tissues. Vd affects peak concentration—a given dose produces higher peaks if Vd is small, lower peaks if Vd is large.
Metabolism: How Peptides Are Broken Down
Metabolism describes how your body chemically modifies and inactivates peptides. Different mechanisms metabolize different peptides.
Enzymatic Degradation
Peptidases (enzymes breaking peptide bonds) are present throughout your body. Plasma peptidases in the bloodstream cleave circulating peptides. Tissue peptidases in tissues break down peptides that reach those tissues. The liver contains numerous peptidases and is a major site of metabolism.
Peptide sequence determines susceptibility to degradation. Peptides with bonds that peptidases preferentially cleave degrade quickly. Peptides with resistant bonds persist longer. This is why researchers modify peptides with unnatural amino acids or unusual bonds—to make them resistant to degradation.
The N-terminus and C-terminus (the ends of peptide chains) are particularly susceptible to enzymatic attack. Exopeptidases preferentially cleave from the ends. Modifications at the ends (like adding chemical groups) can protect peptides.
Oxidative Metabolism
Some peptides undergo oxidation by enzymes like cytochrome P450 in the liver. These enzymes add oxygen atoms, breaking peptide bonds and inactivating peptides. Different individuals have different amounts of these enzymes due to genetic variation, affecting metabolism rate.
Metabolism Rate Variation
Some peptides are rapidly metabolized (half-life of minutes). Others are slowly metabolized (half-life of hours or days). Half-life is the time for peptide concentration to drop to 50% of peak.
Rapidly metabolized peptides require frequent dosing to maintain effective levels. A peptide with 10-minute half-life requires dosing every 30-60 minutes to maintain steady state. Slowly metabolized peptides with 24-hour half-life can be dosed once daily.
Genetic variation affects metabolism rate. Some individuals have genetic variations in peptidase genes, affecting enzyme amounts or activity. Poor metabolizers of certain peptides might accumulate high levels on standard doses. Ultra-rapid metabolizers might require higher doses.
Liver and kidney function affects metabolism. People with liver disease metabolize peptides slowly, possibly requiring dose reduction. People with kidney disease accumulate metabolites, possibly requiring dose reduction.
Drug interactions affect metabolism. Some medications inhibit peptidases, slowing peptide metabolism and increasing levels. Other medications induce peptidases, increasing metabolism and decreasing levels. This is why medications interaction checking matters.
Elimination: How Peptides Exit Body
After metabolism, peptide fragments and metabolites must be eliminated. The kidneys are the primary elimination route for water-soluble compounds.
Renal Elimination
The kidneys filter small water-soluble molecules from blood into urine. Intact peptides (if small enough) and metabolites are eliminated this way. Peptides bound to large carrier proteins don’t filter efficiently because the protein complex is too large. This is why protein binding extends peptide circulation time—binding prevents filtration.
Renal function varies with age, disease, and medications. Reduced kidney function slows elimination, allowing peptide accumulation. This is why dosing adjustments are sometimes needed in kidney disease.
Hepatic Elimination
The liver metabolizes peptides and eliminates metabolites through bile. Some metabolites are excreted in bile and reach the feces. Some undergo enterohepatic recirculation—they’re reabsorbed in the intestine and return to the liver. This recirculation extends elimination time.
Other Routes
Some metabolites are eliminated through other routes: exhalation (for volatile metabolites), skin (through sweat), or other minor routes. These routes are usually minor compared to kidney and liver elimination.
Steady State and Accumulation
When peptides are dosed repeatedly, accumulation occurs if the elimination rate is slower than the dosing interval. After several doses, peptide concentration plateaus at steady state where dose amount equals elimination amount.
Peptides with short half-lives reach steady state quickly (after 3-5 doses) but require frequent dosing. Peptides with long half-lives take longer to reach steady state (after many days) but require less frequent dosing.
Continuous exposure (like long-acting injectable formulations) produces different steady-state concentrations than intermittent dosing. Continuous delivery maintains steady levels without peaks and troughs.
Individual Variation in Bioavailability
Bioavailability varies among individuals due to genetic differences, health differences, and drug interactions. Some individuals have genetic variations in transporters affecting peptide absorption. Others have genetic variations in metabolizing enzymes affecting metabolism rate.
Health conditions affect bioavailability. Gastrointestinal disease affecting absorption might reduce oral peptide bioavailability. Liver disease reduces metabolism. Kidney disease reduces elimination.
Meals affect oral peptide bioavailability. Some peptides absorb better with food. Others absorb better on empty stomach. Food affects stomach emptying, pH, and enzyme secretion—all affecting peptide absorption.
Age affects bioavailability. Older individuals often have reduced kidney and liver function, affecting elimination. Children have different enzyme amounts, affecting metabolism.
Clinical Implications of Bioavailability
Bioavailability knowledge helps optimize peptide effectiveness. For peptides with poor oral bioavailability, injection is necessary to achieve therapeutic levels. For peptides with good oral bioavailability, oral administration is convenient and effective.
Meal timing matters for some peptides. Understanding whether food helps or hinders absorption helps optimize dosing time. Dose timing relative to other medications affects interactions.
Individual variation means standard doses might not be optimal. Some individuals need less to achieve effects. Others need more. Understanding your individual metabolism helps find optimal dosing.
